Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vutiglabridin in Knee Osteoarthritis
NCT06845553Phase 2Recruiting
- Sponsor
- Glaceum
- Start
- Aug 2025
- Primary completion
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of vutiglabridin in knee osteoarthritis (OA) (3 arms), sponsored by Glaceum. Primary endpoint: Visual Analog Scale for Pain at 26 weeks. Started Aug 2025; status: recruiting.
02
Drugs
vutiglabridin
03
Conditions
knee osteoarthritis (OA)
Beyond the preview
Go deeper on NCT06845553.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06845553.